Table 1.

Study population and tumor characteristics

Patient #	Age	Sex	Tumor classification	PDL1 Status	ALK	EGFR
1	87	F	NSCLC-adeno	P (HI, >50%)	N	N
2	74	F	NSCLC-squamous	P (LOW, 1%–49%)	N	N
3	62	F	NSCLC-squamous	P (LOW, 1%–49%)	NA	NA
4	65	M	NSCLC-adeno	N (<1%)	NA	N
5	53	M	NSCLC-adeno	P (LOW, 1%–49%)	N	N
6	68	M	Mixed SCLC/NSCLC	NA	NA	NA
7	60	M	NSCLC-squamous	N (<1%)	N	N
8	81	F	NSCLC-adeno	P (HI, >50%)	N	N
9	73	F	NSCLC-squamous	P (HI, >50%)	N	N
10	63	F	NSCLC-adeno	P (LOW, 1%–49%)	N	P
11	78	M	NSCLC-adeno	P (HI, >50%)	N	N
12	79	F	NSCLC-adeno	N (<1%)	N	N
13	76	F	NSCLC-large cell neuroendocrine	NA	NA	NA
14	64	M	SCLC	NA	NA	NA
15	76	F	NSCLC-adeno	P (HI, >50%)	N	N
16	63	M	NSCLC-squamous	P (LOW, 1%–49%)	NA	NA

High-positive (HI); TPS ≥50%. Low-positive (LOW); TPS ≥1% and≤49%. Negative; TPS <1%.

adeno, adenocarcinoma; ALK, Anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; N, negative status; NA, not available; NSCLC, non-small cell lung cancer; P, positive status; SCLC, small-cell lung cancer; TPS, Tumor Proportion Score.